<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00116584</url>
  </required_header>
  <id_info>
    <org_study_id>GRNT040954</org_study_id>
    <secondary_id>GRNT040954</secondary_id>
    <secondary_id>G040954</secondary_id>
    <nct_id>NCT00116584</nct_id>
  </id_info>
  <brief_title>Heliox-Driven Racemic Epinephrine in Treatment of Bronchiolitis in Pediatric ED Patients</brief_title>
  <official_title>The Use of Heliox Driven Racemic Epinephrine Nebulization in the Treatment of Moderate to Severe Bronchiolitis in Pediatric Emergency Department Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Louisville</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Louisville</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess whether children with moderate to severe bronchiolitis
      treated with standard racemic epinephrine therapy via 70:30 helium-oxygen (heliox) driven
      nebulization will have improvements in measurements of airway more rapidly than those treated
      with conventional air-oxygen driven nebulization.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2004</start_date>
  <completion_date type="Actual">October 2011</completion_date>
  <primary_completion_date type="Actual">March 2008</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Modified Wood's Clinical Asthma Score (M-WCAS) From Baseline to 240 Minutes</measure>
    <time_frame>240 Minutes</time_frame>
    <description>The Modified Wood's clinical Asthma Score is a score to measure severity of Asthma in children. There are 5 variables measured: oxygen saturation, inspiratory breath sounds, expiratory wheezing, accessory muscle involvement and cerebral function. Each variable is given a score of 0, 0.5, 1 or 2 with 2 being the most severe. The scores are combined from each variable to give a total. Total score ranges from 0 to 10, with a score of 10 (higher the score) indicating a worse outcome. We are reporting the degree of improvement in M-WCAS after assigned treatment.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Modified Wood's Clinical Bronchiolitis Score (MWCBS) Between Oxygen and Heliox Groups at Various Times</measure>
    <time_frame>0, 60, 120, 180 and 240 min</time_frame>
    <description>The Modified Wood's Clinical Bronchiolitis Score is based on a rating of saturated oxygen, inspiratory breath sounds, expiratory wheezing, accessory muscle use, cerebral function and wheezing. Each variable is rated 0, 0.5, 1, or 2. The total range of score is 0 to 2, with 2 (higher the score) indicating a worse outcome. For this outcome, a negative difference between groups represents an improvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Respiratory Distress Assessment Instrument (RDAI) Scores in Oxygen and Heliox Groups at Different Times</measure>
    <time_frame>0, 60, 120, 180 and 240 mins</time_frame>
    <description>The RDAI is an assessment instrument for respiratory distress. Patients are assigned a point value based on Wheezing (on expiration, inspiration and location) and Retractions (local of supraclavicular, intercostal and subcostal). Each subcategory is assigned a value of 0-4. The subscores are summed to give a total score for each variable (wheezing and retractions). The total score range for wheezing is 0 to 8, with 8 (higher the score) indicating a worse outcome. The total score range for retractions is 0 to 9, with 9 (higher the score) indicating a worse outcome. We are reporting the difference in score between the groups at various times, not a change from an earlier time. A positive value represents an improvement in the Heliox vs the Oxygen groups.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">72</enrollment>
  <condition>Bronchiolitis</condition>
  <arm_group>
    <arm_group_label>heliox</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>heliox-driven nebulizations for children with moderate to severe bronchiolitis</description>
  </arm_group>
  <arm_group>
    <arm_group_label>oxygen</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>oxygen-driven nebulizations for children with moderate to severe bronchiolitis</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>heliox</intervention_name>
    <description>continuous heliox therapy</description>
    <arm_group_label>heliox</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>oxygen</intervention_name>
    <description>continuous oxygen therapy</description>
    <arm_group_label>oxygen</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Any child 2-12 months old seen in the emergency department.

          -  A clinical bronchiolitis score &gt; 3 by modified Wood's Clinical Bronchiolitis Score
             (M-WCBS).

          -  Diagnostic criteria of bronchiolitis includes tachypnea, cough, prolonged expiratory
             phase, wheezing, rales, chest retractions, and hyperinflation of lungs on chest
             radiograph. After consenting a patient to the study, respiratory syncytial virus (RSV)
             infection will be tested by rapid enzyme-linked immunoabsorbent assay of nasal
             secretions.

        Exclusion Criteria:

          -  No child will be excluded based on race or gender

          -  Patients under the age of 2 months or greater than 12 months

          -  Patients with cyanotic heart disease

          -  Patients with lobar pneumonia, defined by results of chest radiographs.

          -  The presence of interstitial disease or diffuse patchy marking consistent with
             atelectasis on chest radiographs will not exclude patients.

          -  Patients with croup.

          -  Patients with foreign body aspiration.

          -  Patients with history of cystic fibrosis, bronchopulmonary dysplasia or other chronic
             lung disease.

          -  Patients with liver or renal disease.

          -  Patients with sickle cell anemia.

          -  Patients requiring mechanical ventilation.

          -  Patients who develop supraventricular tachycardia secondary to racemic epinephrine
             administration.

          -  Patients with tracheomalacia or bronchomalacia.

          -  Patients who had received bronchodilators within 2 hours of initiation of the study.

          -  Patients who had received systemic corticosteroids within 72 hours of enrollment

          -  Patients who suffered from persistent airway hyperreactivity in the 3 months before
             the study.

          -  Patients who do not tolerate the nasal cannulae for 45 out of 60 minutes.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Months</minimum_age>
    <maximum_age>12 Months</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>In K Kim, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Louisville, Dept. of Pediatrics, Div. of Pediatric Emergency Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Kosair Children's Hospital</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Kim IK, Phrampus E, Sikes K, Pendleton J, Saville A, Corcoran T, Gracely E, Venkataraman S. Helium-oxygen therapy for infants with bronchiolitis: a randomized controlled trial. Arch Pediatr Adolesc Med. 2011 Dec;165(12):1115-22. doi: 10.1001/archpediatrics.2011.605.</citation>
    <PMID>22147778</PMID>
  </results_reference>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>June 29, 2005</study_first_submitted>
  <study_first_submitted_qc>June 29, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 30, 2005</study_first_posted>
  <results_first_submitted>August 19, 2013</results_first_submitted>
  <results_first_submitted_qc>May 8, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">May 20, 2020</results_first_posted>
  <last_update_submitted>May 8, 2020</last_update_submitted>
  <last_update_submitted_qc>May 8, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 20, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Louisville</investigator_affiliation>
    <investigator_full_name>In K. Kim</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>heliox</keyword>
  <keyword>bronchiolitis</keyword>
  <keyword>racemic epinephrine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bronchiolitis</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>This study was conducted from October 1, 2004 through May 31, 2008 in the emergency department of an urban, tertiary care children's hospital.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Heliox</title>
          <description>Patients were randomized to the helium-oxygen received nebulized racemic epinephrine via a face mask.</description>
        </group>
        <group group_id="P2">
          <title>Oxygen</title>
          <description>Patients were randomized to 100% oxygen group and received nebulized racemic epinephrine via a face mask.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="36"/>
                <participants group_id="P2" count="36"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="34"/>
                <participants group_id="P2" count="35"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Seventy-two subjects initially met inclusion criteria; but only 69 were in final analysis.</population>
      <group_list>
        <group group_id="B1">
          <title>Heliox</title>
          <description>heliox-driven nebulizations for children with moderate to severe bronchiolitis</description>
        </group>
        <group group_id="B2">
          <title>Oxygen</title>
          <description>Oxygen nebulizations for children with moderate to severe bronchiolitis</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="34"/>
            <count group_id="B2" value="35"/>
            <count group_id="B3" value="69"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Months</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5.09" lower_limit="2" upper_limit="12"/>
                    <measurement group_id="B2" value="6.11" lower_limit="2" upper_limit="12"/>
                    <measurement group_id="B3" value="5.6" lower_limit="2" upper_limit="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="22"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                    <measurement group_id="B2" value="24"/>
                    <measurement group_id="B3" value="47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Modified Wood's Clinical Asthma Score (M-WCAS) From Baseline to 240 Minutes</title>
        <description>The Modified Wood's clinical Asthma Score is a score to measure severity of Asthma in children. There are 5 variables measured: oxygen saturation, inspiratory breath sounds, expiratory wheezing, accessory muscle involvement and cerebral function. Each variable is given a score of 0, 0.5, 1 or 2 with 2 being the most severe. The scores are combined from each variable to give a total. Total score ranges from 0 to 10, with a score of 10 (higher the score) indicating a worse outcome. We are reporting the degree of improvement in M-WCAS after assigned treatment.</description>
        <time_frame>240 Minutes</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Heliox</title>
            <description>heliox-driven nebulizations for children with moderate to severe bronchiolitis</description>
          </group>
          <group group_id="O2">
            <title>Oxygen</title>
            <description>Oxygen nebulizations for children with moderate to severe bronchiolitis</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Modified Wood's Clinical Asthma Score (M-WCAS) From Baseline to 240 Minutes</title>
          <description>The Modified Wood's clinical Asthma Score is a score to measure severity of Asthma in children. There are 5 variables measured: oxygen saturation, inspiratory breath sounds, expiratory wheezing, accessory muscle involvement and cerebral function. Each variable is given a score of 0, 0.5, 1 or 2 with 2 being the most severe. The scores are combined from each variable to give a total. Total score ranges from 0 to 10, with a score of 10 (higher the score) indicating a worse outcome. We are reporting the degree of improvement in M-WCAS after assigned treatment.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="34"/>
                <count group_id="O2" value="35"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.84" lower_limit="0" upper_limit="10"/>
                    <measurement group_id="O2" value=".031" lower_limit="0" upper_limit="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.05</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Modified Wood's Clinical Bronchiolitis Score (MWCBS) Between Oxygen and Heliox Groups at Various Times</title>
        <description>The Modified Wood's Clinical Bronchiolitis Score is based on a rating of saturated oxygen, inspiratory breath sounds, expiratory wheezing, accessory muscle use, cerebral function and wheezing. Each variable is rated 0, 0.5, 1, or 2. The total range of score is 0 to 2, with 2 (higher the score) indicating a worse outcome. For this outcome, a negative difference between groups represents an improvement.</description>
        <time_frame>0, 60, 120, 180 and 240 min</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Heliox</title>
            <description>heliox-driven nebulizations for children with moderate to severe bronchiolitis</description>
          </group>
          <group group_id="O2">
            <title>Oxygen</title>
            <description>Oxygen nebulizations for children with moderate to severe bronchiolitis</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Modified Wood's Clinical Bronchiolitis Score (MWCBS) Between Oxygen and Heliox Groups at Various Times</title>
          <description>The Modified Wood's Clinical Bronchiolitis Score is based on a rating of saturated oxygen, inspiratory breath sounds, expiratory wheezing, accessory muscle use, cerebral function and wheezing. Each variable is rated 0, 0.5, 1, or 2. The total range of score is 0 to 2, with 2 (higher the score) indicating a worse outcome. For this outcome, a negative difference between groups represents an improvement.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="34"/>
                <count group_id="O2" value="35"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Differenceof MWCBS at 0 mins</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.33" lower_limit="-0.71" upper_limit="0.59"/>
                    <measurement group_id="O2" value="0" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Difference of MWCBS at 60 mins</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.54" lower_limit="0.18" upper_limit="0.91"/>
                    <measurement group_id="O2" value="0" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Difference of MWCBS at 120 mins</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.77" lower_limit="0.45" upper_limit="1.09"/>
                    <measurement group_id="O2" value="0" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Difference of MWCBS at 180 mins</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.94" lower_limit="0.63" upper_limit="1.26"/>
                    <measurement group_id="O2" value="0" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Difference of MWCBS at 240 mins</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.20" lower_limit="0.87" upper_limit="1.54"/>
                    <measurement group_id="O2" value="0" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.05</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Respiratory Distress Assessment Instrument (RDAI) Scores in Oxygen and Heliox Groups at Different Times</title>
        <description>The RDAI is an assessment instrument for respiratory distress. Patients are assigned a point value based on Wheezing (on expiration, inspiration and location) and Retractions (local of supraclavicular, intercostal and subcostal). Each subcategory is assigned a value of 0-4. The subscores are summed to give a total score for each variable (wheezing and retractions). The total score range for wheezing is 0 to 8, with 8 (higher the score) indicating a worse outcome. The total score range for retractions is 0 to 9, with 9 (higher the score) indicating a worse outcome. We are reporting the difference in score between the groups at various times, not a change from an earlier time. A positive value represents an improvement in the Heliox vs the Oxygen groups.</description>
        <time_frame>0, 60, 120, 180 and 240 mins</time_frame>
        <population>The Respiratory Distress Assessment Instrument (RDAI) has been used extensively. It is one of the most commonly used clinical scores for bronchiolitis,.</population>
        <group_list>
          <group group_id="O1">
            <title>Heliox</title>
            <description>heliox-driven nebulizations for children with moderate to severe bronchiolitis</description>
          </group>
          <group group_id="O2">
            <title>Oxygen</title>
            <description>Oxygen nebulizations for children with moderate to severe bronchiolitis</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Respiratory Distress Assessment Instrument (RDAI) Scores in Oxygen and Heliox Groups at Different Times</title>
          <description>The RDAI is an assessment instrument for respiratory distress. Patients are assigned a point value based on Wheezing (on expiration, inspiration and location) and Retractions (local of supraclavicular, intercostal and subcostal). Each subcategory is assigned a value of 0-4. The subscores are summed to give a total score for each variable (wheezing and retractions). The total score range for wheezing is 0 to 8, with 8 (higher the score) indicating a worse outcome. The total score range for retractions is 0 to 9, with 9 (higher the score) indicating a worse outcome. We are reporting the difference in score between the groups at various times, not a change from an earlier time. A positive value represents an improvement in the Heliox vs the Oxygen groups.</description>
          <population>The Respiratory Distress Assessment Instrument (RDAI) has been used extensively. It is one of the most commonly used clinical scores for bronchiolitis,.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="34"/>
                <count group_id="O2" value="35"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Difference between RDAI at 0 min</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.48" lower_limit="-1.55" upper_limit="0.59"/>
                    <measurement group_id="O2" value="0" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Difference of RDAI at 60 mins</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.80" lower_limit="0.55" upper_limit="3.07"/>
                    <measurement group_id="O2" value="0" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Difference of RDAI at 120 mins</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.92" lower_limit="1.77" upper_limit="4.07"/>
                    <measurement group_id="O2" value="0" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Difference of RDAI at 180 mins</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.00" lower_limit="1.99" upper_limit="4.01"/>
                    <measurement group_id="O2" value="0" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Difference of RDAI at 240 mins</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.29" lower_limit="2.35" upper_limit="4.23"/>
                    <measurement group_id="O2" value="0" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.05</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Heliox</title>
          <description>heliox-driven nebulizations for children with moderate to severe bronchiolitis</description>
        </group>
        <group group_id="E2">
          <title>Oxygen</title>
          <description>Oxygen nebulizations for children with moderate to severe bronchiolitis</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. In Kim</name_or_title>
      <organization>ULouisville</organization>
      <phone>502-629-7212</phone>
      <email>in.kim@louisville.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

